real-time news and commentary for investors
Tuesday, Sep 10
Neurocrine Biosciences defended at Jefferies
- Jefferies joins Deutsche Bank and Morgan Stanley in shrugging off Neurocrine Biosciences' (NBIX -29.4%) Phase 2 NBI-98854 setback.
- Analyst Thomas Wei points to the apparently efficacious 100mg dose, although he does conceded that the failure "raises the risk profile around the drug."
- Wei nevertheless maintains a Buy rating and a $16 price target, as '854 is written-off as "upside to valuation."